By a News Reporter-Staff News Editor at Pharma Business Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Mapi – Pharma Ltd (Form FWP) was posted on June 30, 2014.
The SIC code for this company is 2834, Pharmaceutical Preparations.
There were 29 documents filed with this form. The SEC file number is 0001178913-14-002187.
The contact information for this company is 16 EINSTEIN ST., P.O BOX 4113, WEIZMANN SCIENCE PARK, NESS ZIONA L3 74140, 972-73-7121213.
Our editors provided additional information about Form FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/1595380/0001178913-14-002187-index.html.
Keywords for this news article include: Pharmaceutical Preparations, SEC Filing, Mapi – Pharma Ltd.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Mapi – Pharma Ltd Files SEC Form FWP, Filing Under Securities Act Rules 163/433 of Free Writing Prospectuses (Jun. 30, 2014)
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission
- 1 min Read
- 07.9.2014
Why distillate crack spreads will likely experience more volatility.
When people talk about interest rates, real estate prices, and cyclical and secular trends, there’s one piece of context they tend not to mention.
The saying that there is no such thing as a free lunch is very much true for Robinhood.
Another Black Swan event is taking place right now. And it’s likely to have a similar effect on uranium prices.
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
Of course, I couldn’t envision the extent to which AI would take off when I initially urged you to buy Nvidia.
